Download PDF
Arthritis und Rheuma 2018; 38(02): 125-131
DOI: 10.1055/s-0038-1649292
Kinderrheumatologie
Schattauer GmbH

Systemisch inflammatorische Erkrankungen als Differenzialdiagnose in der Neugeborenenperiode – Inflammasom-vermittelte Erkrankungen

Systemic inflammatory diseases as differential diagnosis in new born period Inflammasom-related diseases
C. M. Hedrich
1   Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Deutschland
2   Institute of Translational Medicine, Department of Women’s and Children’s Health, University of Liverpool, Liverpool, United Kingdom
3   Department of Paediatric Rheumatology, Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool, United Kingdom
,
S. R. Hofmann
1   Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Deutschland
,
N. Bruck
1   Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Deutschland
,
G. Hahn
4   Institut und Poliklinik für Radiologische Diagnostik, Bereich Kinderradiologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Deutschland
,
A. Rösen-Wolff
1   Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
27 April 2018 (online)

    Permissions and Reprints

Zusammenfassung

Autoinflammatorische Erkrankungen sind durch systemische oder organbezogene Entzündung gekennzeichnet, welche zumindest initial von fehlregulierten Mechanismen des angeborenen Immunsystems ausgehen. Einige monogene autoinflammatorische Erkrankungen manifestieren in der Perinatalperiode, sodass sie Differenzialdiagnosen zu Infektionen des Neugeborenen darstellen. Im vorliegenden Artikel werden Einblicke in die klinische Präsentation und die molekulare Pathophysiologie Inflammasom-vermittelter monogener Erkrankungen mit Manifestation im Neugeborenenalter gegeben.

Summary

Autoinflammatory conditions are characterized by systemic or organ specific inflammation which is at least initially caused by dysregulation of innate immune mechanisms. Several monogenic autoinflammatory conditions manifest in the perinatal period which makes them differential diagnoses to infections of the newborn. Here, an overview of the clinical presentation and molecular pathophysiology of inflammasome-associated monogenic disorders with manifestation in the newborn period will be given.

Schlüsselwörter

Autoinflammation - Diagnose - Inflammation - Inflammasom - NLRP3 - NLRC4 - CNO - Majeed - DIRA - Biomarker - Therapie

Keywords

Autoinflammation - diagnosis - inflammation - inflammasome - NLRP3 - NLRC4 - CNO - Majeed - DIRA - biomarker - therapy
 

  • Literatur

  • 1 McDermott MF, Aksentijevich I, Galon J. et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97 (01) 133-144.
    CrossrefPubMedGoogle Scholar
  • 2 Hedrich CM. Shaping the spectrum - From autoinflammation to autoimmunity. Clin Immunol 2016; 165: 21-28.
    CrossrefPubMedGoogle Scholar
  • 3 de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol 2015; 33: 823-874.
    CrossrefPubMedGoogle Scholar
  • 4 McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006; 03 (08) e297.
    CrossrefPubMedGoogle Scholar
  • 5 Aksentijevich I, Nowak M, Mallah M. et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46 (12) 3340-3348.
    CrossrefPubMedGoogle Scholar
  • 6 Canna SW, de Jesus AA, Gouni S. et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 2014; 46 (10) 1140-1146.
    CrossrefPubMedGoogle Scholar
  • 7 Duncan JA, Canna SW. The NLRC4 Inflammasome. Immunol Rev 2018; 281 (01) 115-123.
    CrossrefPubMedGoogle Scholar
  • 8 Romberg N, Vogel TP, Canna SW. NLRC4 inflammasomopathies. Curr Opin Allergy Clin Immunol 2017; 17 (06) 398-404.
    CrossrefPubMedGoogle Scholar
  • 9 Winkler S, Hedrich CM, Rosen-Wolff A. [Caspase-1 regulates autoinflammation in rheumatic diseases]. Z Rheumatol 2016; 75 (03) 265-275.
    CrossrefPubMedGoogle Scholar
  • 10 Winkler S, Rosen-Wolff A. Caspase-1: an integral regulator of innate immunity. Semin Immunopathol 2015; 37 (04) 419-427.
    CrossrefPubMedGoogle Scholar
  • 11 El-Shanti H, Ferguson P. et al. Majeed Syndromex. Adam MP, Ardinger HH, Pagon RA. et al. lHrsg. GeneReviews®. Seattle, WA: 1993
    Google Scholar
  • 12 El-Shanti HI, Ferguson PJ. Chronic recurrent multifocal osteomyelitis: a concise review and genetic update. Clin Orthop Relat Res 2007; 462: 11-19.
    CrossrefPubMedGoogle Scholar
  • 13 Morbach H, Hedrich CM, Beer M, Girschick HJ. Autoinflammatory bone disorders. Clin Immunol 2013; 147 (03) 185-196.
    CrossrefPubMedGoogle Scholar
  • 14 Aksentijevich I, Masters SL, Ferguson PJ. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360 (23) 2426-2437.
    CrossrefPubMedGoogle Scholar
  • 15 Aksentijevich I, Putnam CD, Remmers EF. et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56 (04) 1273-1285.
    CrossrefPubMedGoogle Scholar
  • 16 Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep 2011; 13 (02) 123-131.
    CrossrefPubMedGoogle Scholar
  • 17 Grinstein L, Endter K, Hedrich CM. et al. An optimized whole blood assay measuring expression and activity of NLRP3, NLRC4 and AIM2 inflammasomes. Clin Immunol. 2017
    PubMedGoogle Scholar
  • 18 Tanaka N, Izawa K, Saito MK. et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 2011; 63 (11) 3625-3632.
    CrossrefPubMedGoogle Scholar
  • 19 Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Ann Rev Med 2014; 65: 223-244.
    CrossrefPubMedGoogle Scholar
  • 20 Canna SW, Girard C, Malle L. et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol 2017; 139 (05) 1698-1701.
    CrossrefPubMedGoogle Scholar
  • 21 Schnellbacher C, Ciocca G, Menendez R. et al. Deficiency of interleukin-1 receptor antagonist responsive to anakinra. Pediatr Dermatol 2013; 30 (06) 758-760.
    CrossrefPubMedGoogle Scholar
  • 22 Lorden G, Sanjuan-Garcia I, de Pablo N. et al. Lipin-2 regulates NLRP3 inflammasome by affecting P2X7 receptor activation. J Exp Med 2017; 214 (02) 511-528.
    CrossrefPubMedGoogle Scholar
  • 23 Hofmann SR, Kapplusch F, Girschick HJ. et al. Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Curr Osteoporos Rep 2017; 15 (06) 542-554.
    CrossrefPubMedGoogle Scholar
  • 24 Herlin T, Fiirgaard B, Bjerre M. et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013; 72 (03) 410-413.
    CrossrefPubMedGoogle Scholar